Table 4.
Association of side effects with different COVID-19 vaccines.
| Side Effect | Vaccine Type | Phase | Odds Ratio (95% CI) | Included Study | Heterogeneity Test, I-Squared |
|---|---|---|---|---|---|
| Site pain | mRNA-based | 2/3 | 83.06 (37.05–186.1) | 5 | 81.33 |
| 1/2 | 28.26 (16.18–49.35) | 17 | 0 | ||
| Adenovirus-based | 2/3 | 13.64 (8.39–22.17) | 2 | 0 | |
| 1/2 | 3.2 (2.7–4) | 2 | 0 | ||
| Inactivated | 2/3 | 1.73 (0.667–4.5) | 6 | 46.64 | |
| 1/2 | 3.19 (1.3–7.6) | 10 | 52.14 | ||
| Pro-Subunit | 2/3 | 2.14 (1.01–4.5) | 4 | 48.55 | |
| 1/2 | 2.29 (0.48–10.8) | 2 | 29.93 | ||
| Swelling | Adenovirus-based | 1/2/3 | 1.21 (0.77–1.89) | 2 | 0 |
| Inactivated | 1/2/3 | 0.402 (0.056–2.90) | 2 | 0 | |
| Pro-Subunit | 1/2/3 | 6.48 (3.09–13.67) | 5 | 0 | |
| mRNA-based | 1/2/3 | 18.79 (4.87–72.40) | 3 | 59.08 | |
| Redness | Adenovirus-based | 1/2/3 | 1.35 (0.815–2.25) | 4 | 0 |
| Pro-Subunit | 1/2/3 | 7.29 (3.70–14.38) | 6 | 0 | |
| mRNA-based | 1/2/3 | 24.40 (18.73–31.77) | 1 | 0 | |
| Itch | Adenovirus-based | 1/2 | 3.10 (1.96–4.89) | 1 | 0 |
| Inactivated | 1/2 | 0.32 (0.02–5.3) | 1 | 0 | |
| Pro-Subunit | 1/2 | 25.44 (7.85–82.40) | 6 | 0 | |
| Cough | Adenovirus-based | 1/2/3 | 1.76 (1.20–2.58) | 3 | 0 |
| Fever | Adenovirus-based | 1/2/3 | 1.73 (0.57–5.66) | 3 | 90.5 |
| Inactivated | 1/2/3 | 0.27 (0.09–0.76) | 5 | 0 | |
| Pro-Subunit | 1/2/3 | 1.17 (0.73–1.86) | 4 | 0 | |
| mRNA-based | 1/2/3 | 36.90 (12.34–105.21) | 3 | 43.31 | |
| Headache | mRNA-based | 3 | 4.63 (4.4–4.86) | 1 | 0 |
| 2 | 2.32 (1.28–4.19) | 4 | 69.20 | ||
| 1/2 | 5.13 (2.32–11.31) | 5 | 63.02 | ||
| Adenovirus-based | 2 | 2.54 (1.65–3.91) | 2 | 0 | |
| 1/2 | 3.01 (2.35–3.87) | 1 | 0 | ||
| 3 | 0.58 (0.49–0.68) | 1 | 0 | ||
| Inactivated | 2 | 0.18 (0.02–1.14) | 2 | 0 | |
| Pro-Subunit | 2 | 1.25 (0.33–4.7) | 2 | 0 | |
| 1/2 | 1.99 (1.21–3.26) | 14 | 0 | ||
| Fatigue | Adenovirus-based | 1/2 | 2.72 (2.2–3.37) | 3 | 0 |
| Inactivated | 1/2 | 0.39 (0.18–0.82) | 7 | 0 | |
| Pro-Subunit | 1/2 | 2.7 (1.01–7.16) | 4 | 37.2 | |
| mRNA-based | 1/2 | 5.0 (3.42–7.33) | 24 | 48.23 | |
| 2–3 | 4.87 (4.65–5.09) | 1 | 0 | ||
| 3 | 6.16 (5.86–6.48) | 1 | 0 | ||
| Induration | Adenovirus-based | 1/2 | 0.16 (0.05–0.49) | 2 | 46.44 |
| Inactivated | 1/2 | 0.18 (0.06–0.58) | 4 | 0 | |
| Pro-Subunit | 1/2 | 2.62 (1.23–5.58) | 2 | 0 | |
| mRNA-based | 1/2 | 17.5 (1.96–155.58) | 1 | 0 | |
| Vomiting | Adenovirus-based | 1/2 | 2.75 (1.99–3.82) | 3 | 0 |
| Inactivated | 1/2 | 0.32 (0.02–5.38) | 1 | 0 | |
| mRNA-based | 1/2 | 8.71 (4.38–17.34) | 8 | 0 | |
| 2–3 | 4.87 (4.65–5.09) | 1 | 0 | ||
| 3 | 6.16 (5.86–6.48) | 1 | 0 | ||
| Diarrhea | Adenovirus-based | 1/2 | 2.51 (1.12–5.63) | 2 | 0 |
| Inactivated | 1/2 | 0.60 (0.13–2.83) | 3 | 0 | |
| mRNA-based | 1/2 | 0.54 (0.27–1.10) | 5 | 0 | |
| Myalgia | Adenovirus-based | 1/2 | 4.59 (3.58–5.89) | 3 | 0 |
| Inactivated | 1/2 | 1.43 (0.25–8.08) | 2 | 0 | |
| Pro-Subunit | 2.92 (0.57–8.75) | 8 | 53.30 | ||
| mRNA-based | 1/2 | 10.71 (6.51–17.60) | 10 | 33.74 | |
| 2/3 | 7.0 (6.57–7.47) | 1 | 0 | ||
| 3 | 1.43 (0.25–8.08) | 1 | 0 | ||
| Arthralgia | Adenovirus-based | 2/3 | 4.06 (2.99–5.57) | 3 | 0 |
| Pro-Subunit | 2/3 | 1.34 (0.47–3.83) | 4 | 4.833 | |
| mRNA-based | 2/3 | 9.67 (1.27–76.90) | 3 | 67.97 | |
| Chills | Adenovirus-based | 2/3 | 10.61 (7.60–14.83) | 1 | 0 |
| mRNA-based | 2/3 | 13.11 (7.19–23.89) | 8 | 3.82 | |
| Pruritus | Adenovirus-based | 2/3 | 0.54 (0.23–1.25) | 2 | 0 |
| mRNA-based | 2/3 | 17.50 (1.98–155.58) | 1 | 0 |